Exagen Diagnostics and CareFirst BlueCross BlueShield have signed a development agreement to clinically study the former’s AVISE Lupus diagnostic test.
AVISE Lupus is a diagnostic test that comprises cell-bound complement activation products (CB-CAPs) and SLE-related markers.
Members of CareFirst will obtain access to the Lupus test, which is designed to improve the efficiency of systemic lupus erythematosus (SLE), the most common form of lupus and a chronic rheumatic autoimmune disease.
Based in the US, Exagen is a diagnostics company focused on the development of diagnostics for autoimmune connective tissue diseases, while CareFirst, also based in the US, is a healthcare company.
The collaboration will benefit patients suffering from SLE by enabling early diagnosis of the disease and developing appropriate treatment methods.
GN Hearing has partnered with Google to stream audio from Android devices directly to hearing aids.
The technology alliance will enable the users to monitor their hearing aids without using any intermediate device for streaming.
GN Hearing, which is the first hearing aid manufacturer to leverage the new technology, plans to launch its ReSound LiNX Quattro™ and Beltone Amaze™ hearing aids in September.
Based in Denmark, GN is an audio solutions provider and hearing aids manufacturer, while Google is a US-based provider of internet-related services and products.
The partnership will enable the two companies to offer a full spectrum of streaming services for the ReSound LiNX Quattro™ hearing aid users and provide extended support to the Beltone Amaze™ hearing aid.
AngioDynamics has completed the acquisition of the BioSentry Tract Sealant System from Surgical Specialties for an undisclosed sum.
BioSentry™ is the first biopsy tract sealant system developed for the prevention of lung biopsy-related pneumothorax (PTX).
Based in the US, AngioDynamics is a designer and manufacturer of medical diagnostic devices, while Surgical Specialties, also based in the US, is a manufacturer of surgical devices.
The asset transaction is part of the acquirer company’s strategy to expand its oncology portfolio.